FDA Says Eli Lilly Overstates Benefits Of Adcirca

Law360, New York (February 3, 2010, 5:47 PM EST) -- The U.S. Food and Drug Administration has warned Eli Lilly & Co. that marketing materials for its hypertension drug Adcirca overstate its effectiveness and omit information about risks associated with the prescription drug.

The FDA sent warning letters to Eli Lilly and United Therapeutics, which markets Adcirca in the U.S., asking them to immediately stop disseminating a Web page and a patient video about the drug, which is used to treat pulmonary arterial hypertension.

According to the FDA, the Web page discusses the most common side...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.